Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Lead Sponsor:

Eastern Cooperative Oncology Group

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Colorectal Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stoppi...

Detailed Description

OBJECTIVES: * Compare the response rate (complete and partial), progression-free survival, and overall survival of patients with previously untreated metastatic or locally recurrent colorectal adenoc...

Eligibility Criteria

Inclusion

  • INCLUSION:
  • Metastatic or locally recurrent colorectal adenocarcinoma
  • Measurable disease
  • At least 2 formalin-fixed paraffin embedded core needle biopsies OR fine needle aspirate containing a minimum of 3 clusters of malignant cells and fixed tissue from the previous biopsy
  • If no tissue samples are available the patient must be willing to undergo biopsy of a metastatic site
  • Age 18 and over
  • Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
  • Absolute neutrophil count ≥ 1,500/mm\^3
  • Platelet count ≥ 100,000/mm\^3
  • Prothrombin time (PT)/international normalized ratio (INR) ≤ 1.5 unless patient is receiving full-dose anticoagulants AND the following criteria are met:
  • In-range INR (usually between 2 and 3) AND on a stable dose of warfarin or low molecular weight heparin
  • No active bleeding or pathological condition that is associated with a high risk of bleeding
  • Partial thromboplastin time (PTT) \< 1.5 times upper limit of normal (ULN)
  • Alanine transaminase (ALT) and aspartate aminotransferase (AST) \< 3 times ULN
  • Bilirubin ≤ 1.5 times ULN
  • Creatinine ≤ 1.8 mg/dL
  • Meets 1 of the following criteria:
  • Protein negative on urine dipstick
  • Urine protein/creatinine ratio \< 1.0
  • Less than 2 g protein on 24-hour urine collection
  • Patients with a history of hypertension must meet the following criteria:
  • Blood pressure \< 150/90 mm Hg
  • Stable regimen of anti-hypertensive therapy
  • More than 28 days since prior major or open surgery
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after study participation
  • Prior non-colorectal malignancies are allowed provided the following criteria are met:
  • No current clinical evidence of persistent or recurrent disease
  • No active therapy for non-colorectal malignancy, including hormonal therapy
  • EXCLUSION:
  • Pregnant or nursing
  • Arterial thromboembolic events within the past 6 months, including the following:
  • Transient ischemic attack
  • Cerebrovascular accident
  • Unstable angina pectoris
  • Myocardial infarction
  • Symptomatic arrhythmia
  • Symptomatic congestive heart failure
  • Clinically significant peripheral artery disease
  • New York Heart Association class III or IV heart disease
  • Serious nonhealing wound, ulcer, or bone fracture within the past 28 days
  • Significant traumatic injury within the past 28 days
  • Neuropathy ≥ grade 2
  • Ongoing or active infection
  • Concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)
  • Prior chemotherapy for metastatic disease. Adjuvant therapy completed at least 12 months before first evidence of metastasis allowed
  • Cardiovascular, renal, hepatic, or other nonmalignant systemic disease that would preclude study therapy

Exclusion

    Key Trial Info

    Start Date :

    September 8 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 1 2015

    Estimated Enrollment :

    247 Patients enrolled

    Trial Details

    Trial ID

    NCT00098787

    Start Date

    September 8 2005

    End Date

    April 1 2015

    Last Update

    July 5 2023

    Active Locations (110)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 28 (110 locations)

    1

    California Cancer Care, Incorporated - Greenbrae

    Greenbrae, California, United States, 94904

    2

    Aurora Presbyterian Hospital

    Aurora, Colorado, United States, 80012

    3

    Boulder Community Hospital

    Boulder, Colorado, United States, 80301-9019

    4

    Penrose Cancer Center at Penrose Hospital

    Colorado Springs, Colorado, United States, 80933